上海瑞齐发现捷迈（Zimmer）计划$133.5亿收购Biomet

上海瑞齐发现捷迈（Zimmer）计划$133.5亿收购Biomet
2014年4月24日讯   肌肉骨骼健康护理的全球领导者——捷迈（Zimmer）4月24日表示，将耗资约133.5亿美元收购骨科产品公司Biomet，以拓宽其治疗骨骼和关节相关疾病的产品组合。该笔交易预计将于2015年第一季度完成。消息发布后，该公司股价盘前交易中大涨21.1%至110.76美元。

这是本周以来医药领域发生的最新交易。本周发生的其他交易还包括，诺华（Novartis）和葛兰素史克（GSK）同意交易约200亿的资产，而礼来（Eli Lilly）也已同意54亿美元收购诺华动物保健业务。此外，Valeant制药也向艾尔健（Allergan）提出了一份470亿美元的收购要约。

在老龄化人口对Biomet公司生产的人工髋关节和膝关节的需求不断增加、医疗设备市场表现尤为强劲之时，Biomet公司被一家私人股本财团以114亿美元的价格持有。该财团包括黑石集团、高盛资本合伙人基金（GSCP）、KKR集团、德州太平洋集团（TPG），一直在计划将Biomet上市，并已于上个月首次公开招股。

此次收购后，膝关节和髋关节相关业务将成为Zimmer公司最大的2个经营分部，将分别占到总收入的37%和26%，运动医学、四肢创伤及相关产品将成为第3大类，将占到15%。该笔交易中，Zimmer将支付103.5亿美元现金并向Biomet股东发行30亿美元股票。（生物谷Bioon.com）

英文原文：Zimmer to buy Biomet in $13.35 bln deal

(Reuters) - Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio of products that treat bone and joint-related disorders.

Zimmer shares jumped as much as 21.1 percent in premarket trade to $110.76.

The acquisition is the latest in a flurry of deal-making and bids in the healthcare industry this week aimed at either gaining scale or specializing in certain disease areas.

Among the deals, Novartis AG and GlaxoSmithKline Plc agreed to trade some $20 billion in assets, while Eli Lilly and Co agreed to buy Novartis's animal health business for $5.4 billion.

Valeant Pharmaceuticals International Inc also made an unsolicited $47 billion bid for Botox-maker Allergan Inc .

Biomet was taken private for $11.4 billion in 2007 by a private equity consortium when the medical device market was particularly strong on demand from an aging population for the artificial hips and knees that Biomet makes.

The consortium, including affiliates of Blackstone Group , Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co and TPG, had been planning to take the company public, filing for an IPO last month.

After the acquisition, knee and hip-related businesses will be Zimmer's two biggest operating segments, contributing 37 percent and 26 percent of overall revenue.

Sports medicine, extremities and trauma related products will be the third largest category, comprising 15 percent.

Zimmer will pay $10.35 billion in cash and issue $3 billion in shares to Biomet shareholders.

The cash portion of the deal will be funded by cash on hand and $3 billion from a senior unsecured term loan and an issue of senior notes.

Zimmer was advised by Credit Suisse Securities and White & Case LLP on the deal, which is expected to close in the first quarter of 2015.

Biomet was advised by BofA Merrill Lynch, Goldman Sachs, Cleary Gottlieb Steen & Hamilton LLP and Weil, Gotshal & Manges LLP.

Zimmer said the deal is expected to add to adjusted earnings per share in the first year.

Zimmer also reported adjusted quarterly earnings of $1.50 per share, just above Wall Street estimates of $1.47 per share.